(Q39180810)

9 September 2017

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update (English)

1 reference

9 September 2017

Siegfried Segaert

1

1 reference

PMC publication ID

3218722

9 September 2017

language of work or name

English

0 references

publication date

9 August 2009

1 reference

Journal of Inflammation Research

9 September 2017

1 reference

9 September 2017

2

1 reference

9 September 2017

29-36

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

9 September 2017

start time

1 August 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Combining systemic retinoids with biologic agents for moderate to severe psoriasis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Etanercept plus standard therapy for Wegener's granulomatosis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Biology of tumor necrosis factor-alpha- implications for psoriasis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Combination therapy to treat moderate to severe psoriasis.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

An endotoxin-induced serum factor that causes necrosis of tumors

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

UV-DNA damage in mouse and human cells induces the expression of tumor necrosis factor alpha

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Etanercept combined with methotrexate for high-need psoriasis

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

A randomized trial of etanercept as monotherapy for psoriasis.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218722

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

2 December 2018

1 reference

12 December 2020

Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes

1 reference

12 December 2020

Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome

1 reference

12 December 2020

The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy

1 reference

12 December 2020

Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis

1 reference

12 December 2020

Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin

1 reference

12 December 2020

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

1 reference

12 December 2020

Initial experience with routine administration of etanercept in psoriasis

1 reference

12 December 2020

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

12 December 2020

A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index

1 reference

12 December 2020

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

1 reference

12 December 2020

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension

1 reference

12 December 2020

Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis

1 reference

12 December 2020

1 reference

12 December 2020

Novel combination regimens: Biologics and acitretin for the treatment of psoriasis – a case series

1 reference

12 December 2020

Etanercept as monotherapy in patients with psoriasis

1 reference

12 December 2020

Ultraviolet-B-Induced Apoptosis of Keratinocytes: Evidence for Partial Involvement of Tumor Necrosis Factor-α in the Formation of Sunburn Cells

1 reference

12 December 2020

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

1 reference

12 December 2020

Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept

1 reference

12 December 2020

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis

1 reference

12 December 2020

Identifiers

DOI

10.2147/JIR.S4405

1 reference

9 September 2017

1 reference

PMC publication ID

3218722

9 September 2017

PubMed publication ID

22096350

1 reference

PMC publication ID

3218722